Statera Biopharma (STAB) Competitors $0.0001 0.00 (0.00%) As of 05/20/2025 12:45 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock STAB vs. SCPS, EVLO, GNCAQ, GNCA, ARDS, AMPE, CALA, CMRA, EFTR, and CLVRShould you be buying Statera Biopharma stock or one of its competitors? The main competitors of Statera Biopharma include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Ampio Pharmaceuticals (AMPE), Calithera Biosciences (CALA), Comera Life Sciences (CMRA), eFFECTOR Therapeutics (EFTR), and Clever Leaves (CLVR). These companies are all part of the "pharmaceutical products" industry. Statera Biopharma vs. Scopus BioPharma Evelo Biosciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Ampio Pharmaceuticals Calithera Biosciences Comera Life Sciences eFFECTOR Therapeutics Clever Leaves Statera Biopharma (NASDAQ:STAB) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends. Does the media favor STAB or SCPS? In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Statera Biopharma Neutral Scopus BioPharma Neutral Which has more volatility and risk, STAB or SCPS? Statera Biopharma has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.29, indicating that its stock price is 129% less volatile than the S&P 500. Does the MarketBeat Community prefer STAB or SCPS? Scopus BioPharma received 2 more outperform votes than Statera Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformStatera BiopharmaN/AN/AScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo Votes Which has better earnings & valuation, STAB or SCPS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStatera BiopharmaN/AN/AN/AN/AN/AScopus BioPharmaN/AN/A-$11.61MN/AN/A Is STAB or SCPS more profitable? Company Net Margins Return on Equity Return on Assets Statera BiopharmaN/A N/A N/A Scopus BioPharma N/A N/A N/A SummaryStatera Biopharma and Scopus BioPharma tied by winning 1 of the 2 factors compared between the two stocks. Get Statera Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STAB vs. The Competition Export to ExcelMetricStatera BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5,000.00$6.53B$5.38B$8.39BDividend YieldN/A2.65%5.21%4.10%P/E RatioN/A8.9226.8019.71Price / SalesN/A252.24389.55117.28Price / CashN/A65.8538.2534.62Price / BookN/A6.466.804.50Net IncomeN/A$143.98M$3.23B$248.18M7 Day PerformanceN/A2.03%1.53%0.23%1 Month PerformanceN/A4.11%10.05%12.39%1 Year PerformanceN/A-2.87%16.75%7.07% Statera Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STABStatera BiopharmaN/A$0.00flatN/A-85.7%$5,000.00N/A0.0020SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$6,000.00N/A0.00120GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.8%$5,000.00$3.09M0.0030AMPEAmpio PharmaceuticalsN/A$0.00flatN/A-98.8%$3,000.00N/A0.0020Gap UpCALACalithera BiosciencesN/A$0.00+500.0%N/A-97.0%$3,000.00N/A0.0060Analyst ForecastGap UpCMRAComera Life SciencesN/AN/AN/AN/A$3,000.00$1.00M0.002EFTReFFECTOR TherapeuticsN/A$0.00+200.0%N/A-100.0%$3,000.00$3.55M0.0010CLVRClever LeavesN/A$0.00+100.0%N/A-100.0%$1,000.00$17.42M0.00560Gap Up Related Companies and Tools Related Companies Scopus BioPharma Competitors Evelo Biosciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Ampio Pharmaceuticals Competitors Calithera Biosciences Competitors Comera Life Sciences Competitors eFFECTOR Therapeutics Competitors Clever Leaves Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STAB) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Statera Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Statera Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy STAB Stock Free STAB Stock Alerts